Patents by Inventor Frank J. Carr

Frank J. Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant anti-VLA4 antibody molecules
    Patent number: 8226950
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 24, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant Anti-VLA4 Antibody Molecules
    Publication number: 20120022236
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: September 27, 2010
    Publication date: January 26, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant anti-VLA4 antibody molecules
    Patent number: 7829092
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: November 9, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
    Publication number: 20100203042
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: December 18, 2008
    Publication date: August 12, 2010
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Treatment for asthma with ?4-specific antibodies
    Patent number: 7482003
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: January 27, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Treatment for inflammatory bowel disease with ?4-specific antibodies
    Patent number: 7157086
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: January 2, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6752990
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-Tag-72 monoclonal antibodies
    Patent number: 6753420
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Patent number: 6753152
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737061
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737060
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • Recombinant anti-VLA-4 antibody molecules
    Publication number: 20030185819
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Application
    Filed: May 2, 2003
    Publication date: October 2, 2003
    Applicant: Biogen, Inc., a Massachusetts corporation
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Recombinant anti-VLA-4 antibody molecules
    Patent number: 6602503
    Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 5, 2003
    Assignee: Biogen, Inc.
    Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
  • Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
    Publication number: 20030144483
    Abstract: Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.
    Type: Application
    Filed: August 26, 2002
    Publication date: July 31, 2003
    Applicant: Medarex, Inc.
    Inventors: Philip R. Tempest, William J. Harris, Frank J. Carr
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030027994
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: February 6, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030018171
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: January 23, 2003
    Inventors: W.H Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013856
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W.H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013854
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20030004318
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 2, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
    Patent number: 6500931
    Abstract: Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: December 31, 2002
    Assignee: Medarex, Inc.
    Inventors: Philip R. Tempest, William J. Harris, Frank J. Carr